On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of pljučni rak conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes tumor cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb je razkril, da je podjetje FDA in farmacevtski upravi EU predložilo vlogo Opdivo za zdravljenje indikacij pljučnega raka. Seveda se ambiciozno podjetje Squibb ne bo zadovoljilo le s pljučnim rakom in melanomom. Pravzaprav Squibb trenutno izvaja več kot 35 študij zdravila Opdivo samega ali v kombinaciji z drugimi zdravili za zdravljenje različnih vrst tumorjev. Po napovedih analitikov bo prihodnja prodaja Opdiva dosegla kar 5 milijard ameriških dolarjev.
Rak imunoterapija research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Podrobno poročilo v angleščini:
Izjemno imuno-onkološko zdravilo nivolumab podjetja Bristol-Myers Squibb ($ BMY), odobreno prejšnji mesec kot Opdivo, je doseglo izjemen uspeh v preskušanju pljučnega raka v pozni fazi, kar je okrepilo prodajna pričakovanja za pionirsko zdravljenje.
V študiji z 272 bolniki, v kateri je zdravilo Opdivo primerjalo s standardnim uničevalcem raka docetakselom, je zdravilo Bristol-Myers pokazalo tako boljše splošno preživetje v primerjavi s kontrolno skupino, da je doseglo primarno končno točko pred predvidenim rokom, zaradi česar odbor za spremljanje podatkov preskušanja priporoča študijo predčasno zaključiti. Bristol-Myers zdaj vabi bolnike v skupini z docetakselom, da se odločijo za Opdivo prek odprte podaljšane študije.
Zdravljenje Bristol-Myers je zasnovano tako, da spodbudi napad imunskega sistema na tumorje z blokiranjem poti, imenovane PD-1, ki, če je ne nadzoruje, omogoči, da rakave celice preidejo neodkrite s strani naravne obrambe telesa. Tako kot Merckova ($ MRK) podobna Keytruda je tudi Opdivo lani odobril FDA kot zdravilo za zdravljenje melanoma, vendar je zdravilo Bristol-Myers samostojno pri pljučnem raku, saj njegov zadnji klinični uspeh označuje prvič, da je zaviralec PD-1 zabeležil prednost preživetja pred boleznijo, so sporočili iz družbe.
Opdivo’s particular promise in nedrobnocelični pljučni rak has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Podjetje Bristol-Myers je v ZDA in Evropi vložilo prijave za zdravilo Opdivo pri pljučnem raku, pri čemer pričakuje, da bo pozneje letos razširilo uporabo zdravila.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, raka glave in vratu, glioblastoma, Non-Hodgkin lymphoma and other cancers.
